CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Holstein Discusses Mechanism of bb21217 in Myeloma

February 9th 2019

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses the mechanism of action for bb21217 in the treatment of patients with myeloma.

Dr. Shah on the Curative Potential of CAR T-Cell Therapy in Myeloma

February 8th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Maziarz Discusses Promise of Tisagenlecleucel in DLBCL

February 2nd 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses the promise of tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

NICE Recommends Tisagenlecleucel for Relapsed/Refractory DLBCL

February 1st 2019

The UK’s National Institute for Health and Care Excellence has authorized the use of the CAR T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma who have received ≥2 lines of chemotherapy.

Lead Investigator Says Tisagenlecleucel Has Changed Natural History of DLBCL

January 23rd 2019

Richard T. Maziarz, MD, discusses the updated findings from JULIET and their clinical implications for patients with diffuse large B-cell lymphoma.

Dr. Ghobadi Discusses the Logistics of CAR T-Cell Therapy

January 23rd 2019

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Andreadis Discusses FDA-Approved CAR T-Cell Therapies in DLBCL

January 18th 2019

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

Dr. Shah Discusses Challenges With CAR T-Cell Therapy in Myeloma

January 15th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Goy Discusses the Cost of CAR T-Cell Therapy

January 12th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma

January 12th 2019

Nina Shah, MD, discusses the promise of bb21217 in the complex treatment paradigm of relapsed/refractory multiple myeloma

Dr. Neelapu Discusses Efficacy of Axi-Cel in Large B-Cell Lymphoma

January 11th 2019

Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the efficacy of axicabtagene ciloleucel in patients with large B-cell lymphoma.

Dr. Shah Discusses Potential of bb21217 in Multiple Myeloma

January 9th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the potential of bb21217 in the treatment of patients with multiple myeloma.

CAR T-Cell Therapy in Other Disease Settings and Beyond

January 8th 2019

Is the Community Setting Ready for CAR T-Cell Therapy?

January 8th 2019

Outpatient Administration Potential of CAR T-Cell Therapy

January 8th 2019

CAR T-Cell Therapy: Understanding Indicators of Response

January 8th 2019

CAR T-Cell Therapy in Adult Acute Lymphoblastic Leukemia

January 8th 2019

CAR T-Cell Therapy's Role in the ALL Treatment Paradigm

January 8th 2019

Considering Differences Among CAR T-Cell Therapies

January 8th 2019

Practical Applications of CAR T-Cell Therapy in ALL

January 8th 2019